384
Views
0
CrossRef citations to date
0
Altmetric
Technology Report

Multiplex Genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs Using MALDI-TOF Mass Spectrometry

, , , &
Pages 559-571 | Published online: 29 Mar 2010

Bibliography

  • Shastry BS : Pharmacogenetics and the concept of individualized medicine.Pharmacogenomics J.6(1) , 16–21 (2006).
  • Eichelbaum M , Ingelman-SundbergM, EvansWE: Pharmacogenomics and individualized drug therapy.Annu. Rev. Med.57 , 119–137 (2006).
  • Ingelman-Sundberg M , SimSC, GomezA, Rodriguez-AntonaC: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects.Pharmacol. Ther.116(3) , 496–526 (2007).
  • Ingelman-Sundberg M : Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future.Trends Pharmacol. Sci.25(4) , 193–200 (2004).
  • Lamba JK , LinYS, SchuetzEG, ThummelKE: Genetic contribution to variable human CYP3A-mediated metabolism.Adv. Drug. Deliv. Rev.54 , 1271–1294 (2002).
  • van Schaik RH : CYP450 pharmacogenetics for personalizing cancer therapy.Drug Resist. Updat.11(3) , 77–98 (2008).
  • Goldstein JA : Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Br. J. Clin. Pharmacol.52(4) , 349–355 (2001).
  • Kirchheiner J , SeeringerA: Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.Biochim. Biophys. Acta.1770(3) , 489–494 (2007).
  • Veenstra DL , BloughDK, HigashiMK et al.: CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.Clin. Pharmacol. Ther.77(5) , 353–364 (2005).
  • Sim SC , RisingerC, DahlML et al.: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants.Clin. Pharmacol. Ther.79(1) , 103–113 (2006).
  • Ingelman-Sundberg M : Genetic polymorphisms of cytochrome P4502D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity.Pharmacogenomics J.5(1) , 6–13 (2005).
  • Ragoussis J : Genotyping technologies for all.Drug Discov. Today Technologies.3(2) , 115–122 (2006).
  • Ragoussis J , ElvidgeGP, KaurK, ColellaS: Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research.PLoS Genet.2(7) , E100 (2006).
  • Tost J , GutIG: Genotyping single nucleotide polymorphisms by MALDI mass spectrometry in clinical applications.Clin. Biochem.38 , 335–350 (2005).
  • van den Boom D , EhrichM: Discovery and identification of sequence polymorphisms and mutations with MALDI-TOF MS.Methods Mol. Biol.366 , 287–306 (2007).
  • McGuigan FE , RalstonSH: Single nucleotide polymorphism detection: allelic discrimination using TaqMan.Psychiatr. Genet.12(3) , 133–136 (2002).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.